{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:16:19Z","timestamp":1791486979761,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.7759\/cureus.61373","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T17:12:58Z","timestamp":1717089178000},"source":"Crossref","is-referenced-by-count":14,"title":["Advanced Glycation End Products-Induced Alzheimer\u2019s Disease and Its Novel Therapeutic Approaches: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Dhivya","family":"Kothandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutham","family":"Yerrakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Backkiyashree","family":"D","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincy","family":"Santhana Sophia B","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapthami","family":"Ramya VG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshavini","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadheeshwari","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000307","article-title":"Alzheimer disease","volume":"22","author":"Apostolova LG","year":"2016","unstructured":"Apostolova LG. Alzheimer disease. Continuum (Minneap Minn). 2016, 22:419-34. 10.1212\/CON.0000000000000307","journal-title":"Continuum (Minneap Minn)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu C","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009, 11:111-28. 10.31887\/DCNS.2009.11.2\/cqiu","journal-title":"Dialogues Clin Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.105198","article-title":"Incidence of Alzheimer's disease in India: a 10 years follow-up study","volume":"60","author":"Mathuranath PS","year":"2012","unstructured":"Mathuranath PS, George A, Ranjith N, et al.. Incidence of Alzheimer's disease in India: a 10 years follow-up study. Neurol India. 2012, 60:625-30. 10.4103\/0028-3886.105198","journal-title":"Neurol India"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100501","article-title":"Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide","volume":"20 Suppl 2","author":"Vi\u00f1a J","year":"2010","unstructured":"Vi\u00f1a J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis. 2010, 20 Suppl 2:S527-33. 10.3233\/JAD-2010-100501","journal-title":"J Alzheimers Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-010-0122-6","article-title":"Hormonal influences on cognition and risk for Alzheimer's disease","volume":"10","author":"Janicki SC","year":"2010","unstructured":"Janicki SC, Schupf N. Hormonal influences on cognition and risk for Alzheimer's disease. Curr Neurol Neurosci Rep. 2010, 10:359-66. 10.1007\/s11910-010-0122-6","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7361613","article-title":"Overview of Alzheimer\u2019s disease and some therapeutic approaches targeting a\u03b2 by using several synthetic and herbal compounds","volume":"2016","author":"Singh SK","year":"2016","unstructured":"Singh SK, Srivastav S, Yadav AK, Srikrishna S, Perry G. Overview of Alzheimer\u2019s disease and some therapeutic approaches targeting a\u03b2 by using several synthetic and herbal compounds. Oxid Med Cell Longev. 2016, 2016:10.1155\/2016\/7361613","journal-title":"Oxid Med Cell Longev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.684084","article-title":"Truncated amyloid-\u03b2(11-40\/42) from Alzheimer disease binds Cu2+ with a femtomolar affinity and influences fiber assembly","volume":"290","author":"Barritt JD","year":"2015","unstructured":"Barritt JD, Viles JH. Truncated amyloid-\u03b2(11-40\/42) from Alzheimer disease binds Cu2+ with a femtomolar affinity and influences fiber assembly. J Biol Chem. 2015, 290:27791-802. 10.1074\/jbc.M115.684084","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15034671","article-title":"Tau protein modifications and interactions: their role in function and dysfunction","volume":"15","author":"Mietelska-Porowska A","year":"2014","unstructured":"Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014, 15:4671-713. 10.3390\/ijms15034671","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198703000-00006","article-title":"Hirano body filaments contain actin and actin-associated proteins","volume":"46","author":"Galloway PG","year":"1987","unstructured":"Galloway PG, Perry G, Gambetti P. Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol. 1987, 46:185-99. 10.1097\/00005072-198703000-00006","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.20.11839","article-title":"The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures","volume":"270","author":"Shioi J","year":"1995","unstructured":"Shioi J, Pangalos MN, Ripellino JA, Vassilacopoulou D, Mytilineou C, Margolis RU, Robakis NK. The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures. J Biol Chem. 1995, 270:11839-44. 10.1074\/jbc.270.20.11839","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2017.15.1.1","article-title":"Mechanisms of Alzheimer\u2019s disease pathogenesis and Prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors","volume":"15","author":"Kocahan S","year":"2017","unstructured":"Kocahan S, Do\u011fan Z. Mechanisms of Alzheimer\u2019s disease pathogenesis and Prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci. 2017, 15:1-8. 10.9758\/cpn.2017.15.1.1","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000464422","article-title":"Molecular pathogenesis of Alzheimer\u2019s disease: an update","volume":"24","author":"Sanabria-Castro A","year":"2017","unstructured":"Sanabria-Castro A, Alvarado-Echeverr\u00eda I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer\u2019s disease: an update. Ann Neurosci. 2017, 24:46-54. 10.1159\/000464422","journal-title":"Ann Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00204","article-title":"Aberrant insulin signaling in Alzheimer's disease: current knowledge","volume":"9","author":"Bedse G","year":"2015","unstructured":"Bedse G, Di Domenico F, Serviddio G, Cassano T. Aberrant insulin signaling in Alzheimer's disease: current knowledge. Front Neurosci. 2015, 9:204. 10.3389\/fnins.2015.00204","journal-title":"Front Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris LM","year":"2010","unstructured":"Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010, 23:213-27. 10.1177\/0891988710383571","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh VP","year":"2014","unstructured":"Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014, 18:1-14. 10.4196\/kjpp.2014.18.1.1","journal-title":"Korean J Physiol Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0287","article-title":"Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease","volume":"63","author":"Yarchoan M","year":"2014","unstructured":"Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014, 63:2253-61. 10.2337\/db14-0287","journal-title":"Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.096420","article-title":"Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases","volume":"78","author":"Monastero R","year":"2007","unstructured":"Monastero R, Camarda C, Pipia C, Camarda R. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry. 2007, 78:546. 10.1136\/jnnp.2006.096420","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13197-015-1851-y","article-title":"Advanced glycation end-products (AGEs): an emerging concern for processed food industries","volume":"52","author":"Sharma C","year":"2015","unstructured":"Sharma C, Kaur A, Thind SS, Singh B, Raina S. Advanced glycation end-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol. 2015, 52:7561-76. 10.1007\/s13197-015-1851-y","journal-title":"J Food Sci Technol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics6020023","article-title":"Serum levels of toxic ages (TAGE) may be a promising novel biomarker for the onset\/progression of lifestyle-related diseases","volume":"6","author":"Takeuchi M","year":"2016","unstructured":"Takeuchi M. Serum levels of toxic ages (TAGE) may be a promising novel biomarker for the onset\/progression of lifestyle-related diseases. Diagnostics (Basel). 2016, 6:23. 10.3390\/diagnostics6020023","journal-title":"Diagnostics (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biom5010194","article-title":"Advanced glycation end products and oxidative stress in type 2 diabetes mellitus","volume":"5","author":"Nowotny K","year":"2015","unstructured":"Nowotny K, Jung T, H\u00f6hn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015, 5:194-222. 10.3390\/biom5010194","journal-title":"Biomolecules"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2017.1121","article-title":"Glycation damage: a possible hub for major pathophysiological disorders and aging","volume":"9","author":"Fournet M","year":"2018","unstructured":"Fournet M, Bont\u00e9 F, Desmouli\u00e8re A. Glycation damage: a possible hub for major pathophysiological disorders and aging. Aging Dis. 2018, 9:880-900. 10.14336\/AD.2017.1121","journal-title":"Aging Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glq074","article-title":"Does accumulation of advanced glycation end products contribute to the aging phenotype?","volume":"65","author":"Semba RD","year":"2010","unstructured":"Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. J Gerontol A Biol Sci Med Sci. 2010, 65:963-75. 10.1093\/gerona\/glq074","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2010.03.018","article-title":"Advanced glycation end products in foods and a practical guide to their reduction in the diet","volume":"110","author":"Uribarri J","year":"2010","unstructured":"Uribarri J, Woodruff S, Goodman S, et al.. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010, 110:911-16.e12. 10.1016\/j.jada.2010.03.018","journal-title":"J Am Diet Assoc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154922","article-title":"Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases","volume":"27","author":"Yue Q","year":"2022","unstructured":"Yue Q, Song Y, Liu Z, Zhang L, Yang L, Li J. Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases. Molecules. 2022, 27:10.3390\/molecules27154922","journal-title":"Molecules"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10091848","article-title":"Advanced glycation end products in health and disease","volume":"10","author":"Reddy VP","year":"2022","unstructured":"Reddy VP, Aryal P, Darkwah EK. Advanced glycation end products in health and disease. Microorganisms. 2022, 10:1848. 10.3390\/microorganisms10091848","journal-title":"Microorganisms"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020383","article-title":"Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s disease (AD): from risk factors to therapeutic targeting","volume":"9","author":"Paudel YN","year":"2020","unstructured":"Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, Shaikh MF. Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s disease (AD): from risk factors to therapeutic targeting. Cells. 2020, 9:383. 10.3390\/cells9020383","journal-title":"Cells"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-014-0205-5","article-title":"The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach","volume":"19","author":"Salahuddin P","year":"2014","unstructured":"Salahuddin P, Rabbani G, Khan RH. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell Mol Biol Lett. 2014, 19:407-37. 10.2478\/s11658-014-0205-5","journal-title":"Cell Mol Biol Lett"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00067","article-title":"Advanced glycation end products: a molecular target for vascular complications in diabetes","volume":"21 Suppl 1","author":"Yamagishi S","year":"2015","unstructured":"Yamagishi S, Nakamura N, Suematsu M, Kaseda K, Matsui T. Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol Med. 2015, 21 Suppl 1:S32-40. 10.2119\/molmed.2015.00067","journal-title":"Mol Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhh123","article-title":"Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains","volume":"15","author":"L\u00fcth HJ","year":"2005","unstructured":"L\u00fcth HJ, Ogunlade V, Kuhla B, et al.. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex. 2005, 15:211-20. 10.1093\/cercor\/bhh123","journal-title":"Cereb Cortex"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.921611","article-title":"Pyridoxamine and aminoguanidine attenuate the abnormal aggregation of \u03b2-tubulin and suppression of neurite outgrowth by glyceraldehyde-derived toxic advanced glycation end-products","volume":"13","author":"Ooi H","year":"2022","unstructured":"Ooi H, Nasu R, Furukawa A, Takeuchi M, Koriyama Y. Pyridoxamine and aminoguanidine attenuate the abnormal aggregation of \u03b2-tubulin and suppression of neurite outgrowth by glyceraldehyde-derived toxic advanced glycation end-products. Front Pharmacol. 2022, 13:10.3389\/fphar.2022.921611","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2011.4173","article-title":"Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation","volume":"16","author":"Leuner K","year":"2012","unstructured":"Leuner K, Sch\u00fctt T, Kurz C, et al.. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal. 2012, 16:1421-33. 10.1089\/ars.2011.4173","journal-title":"Antioxid Redox Signal"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.150961","article-title":"Proteasome dysfunction induces muscle growth defects and protein aggregation","volume":"127","author":"Kitajima Y","year":"2014","unstructured":"Kitajima Y, Tashiro Y, Suzuki N, et al.. Proteasome dysfunction induces muscle growth defects and protein aggregation. J Cell Sci. 2014, 127:5204-17. 10.1242\/jcs.150961","journal-title":"J Cell Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06826.x","article-title":"The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis","volume":"1281","author":"Padgett LE","year":"2013","unstructured":"Padgett LE, Broniowska KA, Hansen PA, Corbett JA, Tse HM. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci. 2013, 1281:16-35. 10.1111\/j.1749-6632.2012.06826.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.51","article-title":"Is RAGE still a therapeutic target for Alzheimer's disease?","volume":"4","author":"Deane RJ","year":"2012","unstructured":"Deane RJ. Is RAGE still a therapeutic target for Alzheimer's disease?. Future Med Chem. 2012, 4:915-25. 10.4155\/fmc.12.51","journal-title":"Future Med Chem"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2015.15.03.002","article-title":"The role of inflammatory mediators in the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Azizi G","year":"2015","unstructured":"Azizi G, Navabi SS, Al-Shukaili A, Seyedzadeh MH, Yazdani R, Mirshafiey A. The role of inflammatory mediators in the pathogenesis of Alzheimer\u2019s disease. Sultan Qaboos Univ Med J. 2015, 15:e305-16. 10.18295\/squmj.2015.15.03.002","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.030","article-title":"Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases","volume":"177","author":"Byun K","year":"2017","unstructured":"Byun K, Yoo Y, Son M, et al.. Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol Ther. 2017, 177:44-55. 10.1016\/j.pharmthera.2017.02.030","journal-title":"Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.012","article-title":"Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease","volume":"8","author":"C\u00f4t\u00e9 S","year":"2012","unstructured":"C\u00f4t\u00e9 S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2012, 8:219-26. 10.1016\/j.jalz.2011.03.012","journal-title":"Alzheimers Dement"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.6064\/2012\/246210","article-title":"The genetics of Alzheimer's disease","volume":"2012","author":"Barber RC","year":"2012","unstructured":"Barber RC. The genetics of Alzheimer's disease. Scientifica (Cairo). 2012, 2012:246210. 10.6064\/2012\/246210","journal-title":"Scientifica (Cairo)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0476-2","article-title":"Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions","volume":"14","author":"Jayaraman A","year":"2014","unstructured":"Jayaraman A, Pike CJ. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep. 2014, 14:476. 10.1007\/s11892-014-0476-2","journal-title":"Curr Diab Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.05.003","article-title":"Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?","volume":"32","author":"Zhuo JM","year":"2011","unstructured":"Zhuo JM, Wang H, Pratic\u00f2 D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?. Trends Pharmacol Sci. 2011, 32:562-71. 10.1016\/j.tips.2011.05.003","journal-title":"Trends Pharmacol Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160527","article-title":"Stroke, vascular dementia, and Alzheimer\u2019s disease: molecular links","volume":"54","author":"Vijayan M","year":"2016","unstructured":"Vijayan M, Reddy PH. Stroke, vascular dementia, and Alzheimer\u2019s disease: molecular links. J Alzheimers Dis. 2016, 54:427-43. 10.3233\/JAD-160527","journal-title":"J Alzheimers Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer's disease","volume":"430","author":"Mattson MP","year":"2004","unstructured":"Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004, 430:631-9. 10.1038\/nature02621","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.11.006","article-title":"Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms","volume":"3","author":"Stirban A","year":"2014","unstructured":"Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab. 2014, 3:94-108. 10.1016\/j.molmet.2013.11.006","journal-title":"Mol Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-013-0453-1","article-title":"Advanced glycation end products (AGE) and diabetes: cause, effect, or both?","volume":"14","author":"Vlassara H","year":"2014","unstructured":"Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both?. Curr Diab Rep. 2014, 14:453. 10.1007\/s11892-013-0453-1","journal-title":"Curr Diab Rep"},{"key":"ref45","article-title":"Therapeutic interventions against accumulation of advanced glycation end products (AGEs)","volume":"4","author":"Roorda M","year":"2017","unstructured":"Roorda M. Therapeutic interventions against accumulation of advanced glycation end products (AGEs). Glycative Stress Research. 2017, 4:132-43.","journal-title":"Glycative Stress Research"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081852","article-title":"The glyoxalase system in age-related diseases: nutritional intervention as anti-ageing strategy","volume":"10","author":"Aragon\u00e8s G","year":"2021","unstructured":"Aragon\u00e8s G, Rowan S, Francisco SG, et al.. The glyoxalase system in age-related diseases: nutritional intervention as anti-ageing strategy. Cells. 2021, 10:1852. 10.3390\/cells10081852","journal-title":"Cells"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2011.08.005","article-title":"Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics","volume":"1812","author":"Mao P","year":"2011","unstructured":"Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011, 1812:1359-70. 10.1016\/j.bbadis.2011.08.005","journal-title":"Biochim Biophys Acta"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/biohorizons\/hzw014","article-title":"Alzheimer's disease: the role of mitochondrial dysfunction and potential new therapies","volume":"9","author":"Hawking ZL","year":"2016","unstructured":"Hawking ZL. Alzheimer's disease: the role of mitochondrial dysfunction and potential new therapies. Int J Stud Res. 2016, 9:hzw014. 10.1093\/biohorizons\/hzw014","journal-title":"Int J Stud Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4161\/cam.3.1.7402","article-title":"Oxidative stress in Alzheimer disease","volume":"3","author":"Gella A","year":"2009","unstructured":"Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr. 2009, 3:88-93. 10.4161\/cam.3.1.7402","journal-title":"Cell Adh Migr"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/nu2121247","article-title":"Dietary advanced glycation end products and aging","volume":"2","author":"Luevano-Contreras C","year":"2010","unstructured":"Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients. 2010, 2:1247-65. 10.3390\/nu2121247","journal-title":"Nutrients"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2013.12.016","article-title":"Role of advanced glycation end products in cellular signaling","volume":"2","author":"Ott C","year":"2014","unstructured":"Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014, 2:411-29. 10.1016\/j.redox.2013.12.016","journal-title":"Redox Biol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2018.06.005","article-title":"Dietary advanced glycation end products and their relevance for human health","volume":"47","author":"Nowotny K","year":"2018","unstructured":"Nowotny K, Schr\u00f6ter D, Schreiner M, Grune T. Dietary advanced glycation end products and their relevance for human health. Ageing Res Rev. 2018, 47:55-66. 10.1016\/j.arr.2018.06.005","journal-title":"Ageing Res Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1018","article-title":"An update on advanced glycation endproducts and atherosclerosis","volume":"38","author":"Del Turco S","year":"2012","unstructured":"Del Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors. 2012, 38:266-74. 10.1002\/biof.1018","journal-title":"Biofactors"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1330-x","article-title":"Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase","volume":"47","author":"Madonna R","year":"2004","unstructured":"Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia. 2004, 47:532-6. 10.1007\/s00125-004-1330-x","journal-title":"Diabetologia"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.227","article-title":"Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration","volume":"128","author":"Jonas JB","year":"2010","unstructured":"Jonas JB, Tao Y, Neumaier M, Findeisen P. Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol. 2010, 128:1281-6. 10.1001\/archophthalmol.2010.227","journal-title":"Arch Ophthalmol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20023309","article-title":"Prevention of protein glycation by natural compounds","volume":"20","author":"Sadowska-Bartosz I","year":"2015","unstructured":"Sadowska-Bartosz I, Bartosz G. Prevention of protein glycation by natural compounds. Molecules. 2015, 20:3309-34. 10.3390\/molecules20023309","journal-title":"Molecules"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1108\/00346651011076965","article-title":"Vitamin C and urea inhibit the formation of advanced glycation end products in vitro","volume":"40","author":"Subratty AH","year":"2010","unstructured":"Subratty AH, Aukburally N, Jowaheer V, Joonus N. Vitamin C and urea inhibit the formation of advanced glycation end products in vitro. Nutrition & Food Science. 2010, 40:456-65. 10.1108\/00346651011076965","journal-title":"Nutrition & Food Science"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s11103-011-9777-x","article-title":"Identification and characterization of a pyridoxal reductase involved in the vitamin B6 salvage pathway in Arabidopsis","volume":"76","author":"Herrero S","year":"2011","unstructured":"Herrero S, Gonz\u00e1lez E, Gillikin JW, V\u00e9l\u00ebz H, Daub ME. Identification and characterization of a pyridoxal reductase involved in the vitamin B6 salvage pathway in Arabidopsis. Plant Mol Biol. 2011, 76:157-69. 10.1007\/s11103-011-9777-x","journal-title":"Plant Mol Biol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-12","article-title":"Effect of TTP488 in patients with mild to moderate Alzheimer's disease","volume":"14","author":"Burstein AH","year":"2014","unstructured":"Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014, 14:12. 10.1186\/1471-2377-14-12","journal-title":"BMC Neurol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114347","article-title":"Discovery of novel dual RAGE\/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression","volume":"236","author":"Zhang C","year":"2022","unstructured":"Zhang C, Wang L, Xu Y, et al.. Discovery of novel dual RAGE\/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression. Eur J Med Chem. 2022, 236:114347. 10.1016\/j.ejmech.2022.114347","journal-title":"Eur J Med Chem"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2682861","article-title":"Protective effects of pyridoxamine supplementation in the early stages of diet-induced kidney dysfunction","volume":"2017","author":"Chiazza F","year":"2017","unstructured":"Chiazza F, Cento AS, Collotta D, et al.. Protective effects of pyridoxamine supplementation in the early stages of diet-induced kidney dysfunction. Biomed Res Int. 2017, 2017:2682861. 10.1155\/2017\/2682861","journal-title":"Biomed Res Int"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200896","article-title":"Benfotiamine and cognitive decline in Alzheimer\u2019s disease: results of a randomized placebo-controlled Phase IIa clinical trial","volume":"78","author":"Gibson GE","year":"2020","unstructured":"Gibson GE, Luchsinger JA, Cirio R, et al.. Benfotiamine and cognitive decline in Alzheimer\u2019s disease: results of a randomized placebo-controlled Phase IIa clinical trial. J Alzheimers Dis. 2020, 78:989-1010. 10.3233\/JAD-200896","journal-title":"J Alzheimers Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1191719","article-title":"Mechanism of the inhibitory effect of OPB-9195 [(+\/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation","volume":"11","author":"Miyata T","year":"2000","unstructured":"Miyata T, Ueda Y, Asahi K, et al.. Mechanism of the inhibitory effect of OPB-9195 [(+\/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol. 2000, 11:1719-25. 10.1681\/ASN.V1191719","journal-title":"J Am Soc Nephrol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2017.1396200","article-title":"Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents","volume":"59","author":"Alizadeh M","year":"2019","unstructured":"Alizadeh M, Kheirouri S. Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents. Crit Rev Food Sci Nutr. 2019, 59:1169-77. 10.1080\/10408398.2017.1396200","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft S","year":"2020","unstructured":"Craft S, Raman R, Chow TW, et al.. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020, 77:1099-109. 10.1001\/jamaneurol.2020.1840","journal-title":"JAMA Neurol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger MA","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, et al.. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008, 70:440-8. 10.1212\/01.WNL.0000265401.62434.36","journal-title":"Neurology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4530(02)00087-2","article-title":"Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype","volume":"28","author":"Craft S","year":"2003","unstructured":"Craft S, Asthana S, Cook DG, et al.. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003, 28:809-22. 10.1016\/s0306-4530(02)00087-2","journal-title":"Psychoneuroendocrinology"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00853-0","article-title":"Role of liraglutide in Alzheimer's disease pathology","volume":"13","author":"Vargas-Soria M","year":"2021","unstructured":"Vargas-Soria M, Carranza-Naval MJ, Del Marco A, Garcia-Alloza M. Role of liraglutide in Alzheimer's disease pathology. Alzheimers Res Ther. 2021, 13:112. 10.1186\/s13195-021-00853-0","journal-title":"Alzheimers Res Ther"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44763","article-title":"Exploring the potential of antidiabetic agents as therapeutic approaches for Alzheimer\u2019s and Parkinson\u2019s diseases: a comprehensive review","volume":"15","author":"Koshatwar M","year":"2023","unstructured":"Koshatwar M, Acharya S, Prasad R, Lohakare T, Wanjari M, Taksande AB. Exploring the potential of antidiabetic agents as therapeutic approaches for Alzheimer\u2019s and Parkinson\u2019s diseases: a comprehensive review. Cureus. 2023, 15:e44763. 10.7759\/cureus.44763","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253561-advanced-glycation-end-products-induced-alzheimers-disease-and-its-novel-therapeutic-approaches-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T17:13:01Z","timestamp":1717089181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253561-advanced-glycation-end-products-induced-alzheimers-disease-and-its-novel-therapeutic-approaches-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.61373","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}